亚洲、澳大利亚与英国老年人多重用药趋势:跨国人群研究
2016年多重用药患病率以香港最高(46.4%),台湾(38.8%)、韩国(32.0%)次之,英国(23.5%)与澳大利亚(20.1%)较低;亚洲呈上升趋势,澳英呈下降趋势。
要点
- 2016年多重用药患病率香港46.4%最高,澳大利亚20.1%最低。
- 香港、韩国、台湾多重用药呈上升趋势,年平均百分比变化分别为2.7%、1.8%、1.0%。
- 澳大利亚与英国呈下降趋势,年平均百分比变化分别为-4.9%与-1.1%。
核心结论
- 老年人多重用药患病率在香港、台湾和韩国高于澳大利亚与英国,且亚洲呈上升趋势,澳英呈下降趋势。
- 作者强调需通过政府层面干预与药物优化策略监测亚洲老年人的多重用药。
研究设计与样本
- 多国、回顾性、时间趋势、观察性研究,采用统一研究方案。
- 多重用药定义为每年同时使用≥5种药物≥45天,计算年度患病率与年平均百分比变化(AAPC)评估趋势。
主要发现
- 2016年多重用药患病率:香港46.4%、台湾38.8%、韩国32.0%、英国23.5%、澳大利亚20.1%。
- 亚洲地区呈稳定上升,AAPC为香港2.7%、韩国1.8%、台湾1.0%。
- 澳大利亚与英国呈下降趋势,AAPC分别为-4.9%与-1.1%。
关键数值与推荐
- 多重用药定义:每年同时使用≥5种药物≥45天。
- 2016年患病率数值:香港46.4%、台湾38.8%、韩国32.0%、英国23.5%、澳大利亚20.1%。
- 趋势数值(AAPC):香港2.7%、韩国1.8%、台湾1.0%、澳大利亚-4.9%、英国-1.1%。
临床怎么用
- 提示老年医学科医生在亚洲地区(尤其香港、台湾、韩国)就诊的≥65岁患者中应重视多重用药筛查与药物优化。
- 可参考本研究对多重用药的量化定义(≥5种药物、≥45天)统一评估口径。
- 研究提示需政府层面干预与药物优化策略,临床可据此推动所在机构的用药审查流程。
局限性
- 原文摘要未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy among older people represents a global challenge due to its association with adverse drug events. The reported prevalence of polypharmacy varies widely across countries, and is particularly high in Asian countries. However, there is no multinational study using standardised measurements exploring variations in prescribing trends. OBJECTIVE: To compare polypharmacy trends in older people in Asia, Australia and the United Kingdom. DESIGN: Multinational, retrospective, time-trend, observational study using a common study protocol. SETTING: Outpatient and community settings. SUBJECTS: All individuals aged ≥ 65 years between 2013 and 2016. METHODS: We defined polypharmacy as the concomitant use of ≥5 medications for ≥45 days per year. We estimated the annual prevalence of polypharmacy and calculated average annual percentage change (AAPC) to assess the time trends. RESULTS: A total of 1.62 million individuals were included in this study. The highest prevalence of polypharmacy was observed in Hong Kong (46.4%), followed by Taiwan (38.8%), South Korea (32.0%), the United Kingdom (23.5%) and Australia (20.1%) in 2016. For the time trend, the Asian region showed a steady increase, particularly in Hong Kong and South Korea (AAPC: Hong Kong, 2.7%; South Korea, 1.8%; Taiwan, 1.0%). However, Australia and the United Kingdom showed a decreasing trend (Australia, -4.9%; the United Kingdom, -1.1%). CONCLUSIONS: Polypharmacy prevalence in older people was higher in Hong Kong, Taiwan and South Korea, with an increasing trend over time, compared with Australia and the United Kingdom. Our findings underline the necessity to monitor polypharmacy among older people in Asia by conducting government-level interventions and introducing medicine-optimisation strategies.
引用
- Lee H, Baek YH, Kim JH, et al. Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: a multinational population-based study. Age Ageing. 2023. PMID: 36821644. doi:10.1093/ageing/afad014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。